MarginsXMarginsX
Home › Markets › Health Care › CYPH

Cypherpunk Technologies Inc. (CYPH)

CYPH trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.93
+2.94% on the day
Market cap
$207.4M
Micro cap
Revenue · 2021
$1.5M
0.0% on 2020
Net income · 2021
-$40.6M
-2705.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2021-12-31, https://www.sec.gov/Archives/edgar/data/1509745/000110465923036239/0001104659-23-036239-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2021-12-31.

Profile

FieldValue
TickerCYPH on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001509745
SEC industry codeFinance Services
Incorporated inDE

Financials · 2021

LineValue
Revenue$1.5M
Net income-$40.6M
Operating income-$41.4M
Net margin-2705.8%
Operating margin-2761.7%
Revenue growth0.0%
Cash$114.9M
Total assets$117.9M
P/E (computed)Net income was not positive
P/S (computed)138.3×

Warning signs

Cash runway
4.3 months
$7.6M cash at June 30, 2026
Share count, 1 year
+160.1%
2025-08-11 to 2026-08-10 · +321.5% over 3 years
Going-concern doubt
No
10-Q filed August 12, 2026
Insider net buying, 12 months
-$3.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"In accordance with Accounting Standards Codification ( ASC ) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued."
10-Q 2026-08-12
Cash and burn$7.6M cash; operating cash flow -$5.3M a quarter.Report 2026-06-30
Shares outstanding107,764,382 (2026-08-10); 41,439,529 a year earlier; 25,565,414 three years earlier.Cover page 2026-08-10
Reverse splits, 3 years2; latest on 2025-12-16Source 2025-12-16
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-07-21
AuditorEisnerAmper LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $3.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed$39.4M-$2.7M$7.6MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
Not filed-$77.2M-$3.4M$6.7MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q4 2025
2025-12-31
Not filed$40.2M-$6.6M$14.0MNo debt tagsNeeds four quarters10-K 2026-03-16
Q3 2025
2025-09-30
Not filed-$3.3M-$8.3M$9.7MNo debt tagsNeeds four quarters10-Q 2025-11-12
Q2 2025
2025-06-30
Not filed-$16.6M-$14.5M$18.1MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
Not filed-$15.4M-$14.5M$32.7MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q4 2024
2024-12-31
Not filed-$15.4M-$15.5M$47.2MNo debt tagsNeeds four quarters10-K 2026-03-16
Q3 2024
2024-09-30
Not filed-$18.2M-$15.6M$62.8MNo debt tagsNeeds four quarters10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-11-12
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-16
Latest current report
FORM 8-K
8-K2026-11-16
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 625 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-35.1%
1 month-34.2%
3 months+188.6%
Year to date+61.2%
1 year+6.3%
From 52-week high-54.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SIGASIGA Technologies Inc.$2.85+4.01%$204.8M
YARWYarrow Bioscience Inc.$13.93-22.74%$212.2M
ACIUAC Immune SA$2.09-1.88%$212.7M
GLSIGreenwich LifeSciences Inc.$13.76-7.90%$202.0M
VOGXVogenx Inc$14.38-13.74%$213.6M
KROSKeros Therapeutics Inc.$10.03-2.62%$196.8M
NGENNervGen Pharma Corp.$1.82-3.19%$195.9M
TRDAEntrada Therapeutics Inc.$5.00-1.77%$195.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier